Latest filing published 06 Mar 2026 for Sutro Biopharma, INC., €5,083.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
David Pauling discloses dealings in Sutro Biopharma, Inc. to SEC (Form 4). Between 15 October 2025 and 4 March 2026, the trades on record add up to 8 filings.
The open-market record is one-sided, with 1 purchase worth €8,581 and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 3 share grants and 4 option exercises.
The record was last updated on 6 March 2026 with a share grant (€5,083) in Sutro Biopharma, Inc. The last purchase on record was published on 16 October 2025, which is 373 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations